ReviewFrontiers in bioengineering and biotechnology2022
Developing methylotrophic microbial platforms for a methanol-based bioindustry.
Review in Frontiers in bioengineering and biotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 24 citations in OpenAlex.
- Production of β-carotene from methanol via rDNA-targeted multi-gene integration and selection with increasing antibiotic concentrations in Komagataella phaffii.World journal of microbiology & biotechnology · 2026Article
- Systematic metabolic engineering of Komagataella phaffii for methanol-to-lactate bioconversion.Bioprocess and biosystems engineering · 2026Article
- Advances in synthetic biology for engineering methylotrophic microbial cell factories.Journal of bacteriology · 2026Review
- Optimization and scale up of L-malic acid production from methanol by the methylotrophic yeast Ogataea polymorpha.FEMS yeast research · 2026Article
- Yeast Midas' touch: recent advances in the valorisation of methanol by yeasts.World journal of microbiology & biotechnology · 2025Review
- Thermotolerant yeasts promoting climate-resilient bioproduction.FEMS yeast research · 2025Review
- Candida boidinii isolates from olive curation water: a promising platform for methanol-based biomanufacturing.AMB Express · 2024Article
- Efficient production of itaconic acid from the single-carbon substrate methanol with engineered Komagataella phaffii.Biotechnology for biofuels and bioproducts · 2024Article
- Single carbon metabolism - A new paradigm for microbial bioprocesses?Synthetic and systems biotechnology · 2024Review
- Molecular identification of methane-consuming bacteria in the Persian Gulf: a study for microbial gas exploration.Frontiers in microbiology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Methanol, a relatively cheap and renewable single-carbon feedstock, has gained considerable attention as a substrate for the bio-production of commodity chemicals. Conventionally produced from syngas, along with emerging possibilities of generation from methane and CO2, this C1 substrate can serve as a pool for sequestering greenhouse gases while supporting a sustainable bio-economy. Methylotrophic organisms, with the inherent ability to use methanol as the sole carbon and energy source, are competent candidates as platform organisms. Accordingly, methanol bioconversion pathways have been an attractive target for biotechnological and bioengineering interventions in developing microbial cell factories. This review summarizes the recent advances in methanol-based production of various bulk and value-added chemicals exploiting the native and synthetic methylotrophic organisms. Finally, the current challenges and prospects of streamlining these methylotrophic platforms are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.